Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Booth BJ, Batra SK.

J Nucl Med. 2001 Oct;42(10):1519-27.

2.

99mTc-Hydrazinonicotinamide-anti-TAG-72 CC49 tetravalent single-chain Fv monoclonal antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Jun 26 [updated 2007 Dec 28].

3.

Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.

Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, Colcher D, Batra SK.

Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):264-73. Epub 2004 Oct 2.

PMID:
15791435
4.

99mTc-Hydrazinonicotinamide-anti-TAG-72 CC49 divalent single-chain Fv monoclonal antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Jun 19 [updated 2008 Jan 28].

5.

Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.

Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D.

J Nucl Med. 1999 Sep;40(9):1536-46.

6.

Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.

Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK.

Cancer Res. 2000 Dec 15;60(24):6964-71.

7.

Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.

Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK.

Clin Cancer Res. 2001 Jan;7(1):175-84.

8.

Radioiodinated anti-TAG-72 CC49 tetravalent single-chain Fv antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Jul 23 [updated 2008 Jan 22].

9.

Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody.

Beresford GW, Pavlinkova G, Booth BJ, Batra SK, Colcher D.

Int J Cancer. 1999 Jun 11;81(6):911-7.

10.

Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.

Slavin-Chiorini DC, Kashmiri SV, Schlom J, Calvo B, Shu LM, Schott ME, Milenic DE, Snoy P, Carrasquillo J, Anderson K, et al.

Cancer Res. 1995 Dec 1;55(23 Suppl):5957s-5967s.

11.

Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.

Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJ, Baranowska-Kortylewicz J, Batra SK.

J Biochem. 2000 May;127(5):829-36.

12.

Radioiodinated-antiā€“TAG-72 covalently linked CC49 divalent single-chain Fv antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Sep 25 [updated 2007 Oct 30].

14.

Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.

Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J.

Cancer Res. 1993 Aug 15;53(16):3776-83. Erratum in: Cancer Res 1993 Dec 1;53(23):5832.

15.

In vitro and in vivo comparison of binding of 99m-Tc-labeled anti-CEA MAb F33-104 with 99m-Tc-labeled anti-CEA MAb BW431/26.

Watanabe N, Oriuchi N, Sugiyama S, Kuroki M, Matsuoka Y, Tanada S, Murata H, Inoue T, Sasaki Y.

Nuklearmedizin. 1999;38(4):115-9.

PMID:
10392376
16.

The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.

Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK.

Nucl Med Biol. 2005 Feb;32(2):157-64.

PMID:
15721761
17.

Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.

Pavlinkova G, Colcher D, Booth BJ, Goel A, Batra SK.

Cancer Immunol Immunother. 2000 Jul;49(4-5):267-75.

PMID:
10941910
18.

Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.

Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G.

Cancer Biother Radiopharm. 2006 Apr;21(2):106-16.

PMID:
16706631
19.

124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.

Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM.

J Nucl Med. 2003 Dec;44(12):1962-9.

20.

Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.

Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF, Whitlow M, Snoy P, Schlom J.

Cancer Res. 1991 Dec 1;51(23 Pt 1):6363-71.

Supplemental Content

Support Center